Cargando…

Time of onset of atrial fibrillation and atrial fibrillation progression data from the RACE V study

AIMS: Atrial fibrillation (AF) progression is associated with adverse outcome, but the role of the circadian or diurnal pattern of AF onset remains unclear. We aim to assess the association between the time of onset of AF episodes with the clinical phenotype and AF progression in patients with self-...

Descripción completa

Detalles Bibliográficos
Autores principales:	van de Lande, Martijn E, Rama, Rajiv S, Koldenhof, Tim, Arita, Vicente Artola, Nguyen, Bao-Oanh, van Deutekom, Colinda, Weberndorfer, Vanessa, Crijns, Harry J G M, Hemels, Martin E W, Tieleman, Robert G, de Melis, Mirko, Schotten, Ulrich, Linz, Dominik, Van Gelder, Isabelle C, Rienstra, Michiel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10227656/ https://www.ncbi.nlm.nih.gov/pubmed/36967470 http://dx.doi.org/10.1093/europace/euad058

Ejemplares similares

Brady- and tachyarrhythmias detected by continuous rhythm monitoring in paroxysmal atrial fibrillation
por: Frausing, Maria Hee Jung Park, et al.
Publicado: (2023)

Number of comorbidities is associated with symptom severity and arrhythmia progression in paroxysmal atrial fibrillation - Data from the RACE V study
por: Van De Lande, M E, et al.
Publicado: (2023)

Prevalence and determinants of atrial fibrillation progression in paroxysmal atrial fibrillation
por: Nguyen, Bao-Oanh, et al.
Publicado: (2023)

Atrial fibrillation and heart failure temporality: does it matter?
por: Van Deutekom, Colinda, et al.
Publicado: (2022)

Brady- and tachyarrhythmias in paroxysmal atrial fibrillation: results from long-term continuous electrocardiographic monitoring in RACE V
por: Park Frausing, M H J, et al.
Publicado: (2023)

Clinical utility of the 4S-AF scheme in predicting progression of atrial fibrillation: data from the RACE V study
por: Artola Arita, Vicente, et al.
Publicado: (2023)

Rate control with calcium channel blockers versus betablockers in patients with paroxysmal and persistent atrial fibrillation - data from the AFFIRM trial
por: Koldenhof, T, et al.
Publicado: (2023)

Cardiovascular and renal multimorbidity increase risk of atrial fibrillation in the PREVEND cohort
por: Van Deutekom, Colinda, et al.
Publicado: (2023)

Different circulating biomarkers in women and men with paroxysmal atrial fibrillation: results from the AF-RISK and RACE V studies
por: De With, Ruben R, et al.
Publicado: (2021)

Temporal patterns and short-term progression of paroxysmal atrial fibrillation: data from RACE V
por: De With, Ruben R, et al.
Publicado: (2020)

Incidence and outcome of atrial fibrillation: diversity throughout Europe
por: Rienstra, Michiel, et al.
Publicado: (2021)

Rate control drugs differ in the prevention of progression of atrial fibrillation
por: Koldenhof, Tim, et al.
Publicado: (2021)

Cardioversion of atrial fibrillation and atrial flutter revisited: current evidence and practical guidance for a common procedure
por: Brandes, Axel, et al.
Publicado: (2020)

Heart rate increase and inappropriate sinus tachycardia after cryoballoon pulmonary vein isolation for atrial fibrillation
por: van Deutekom, C., et al.
Publicado: (2021)

Cardioversion strategy impacts quality of rate control during recurrences of atrial fibrillation
por: Van Der Velden, R, et al.
Publicado: (2023)

Prevalence and Incidence of Atrial Fibrillation in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: (Additive) Value of Implantable Loop Recorders
por: Gorter, Thomas M., et al.
Publicado: (2023)

New concepts in atrial fibrillation pathophysiology
por: Hermans, Ben J. M., et al.
Publicado: (2022)

Initial experience with pulsed field ablation for atrial fibrillation
por: Magni, Federico T., et al.
Publicado: (2022)

Update on management of atrial fibrillation in heart failure: a focus on ablation
por: Mulder, Bart A, et al.
Publicado: (2022)

Telomere length and incident atrial fibrillation – data of the PREVEND cohort
por: Siland, Joylene E., et al.
Publicado: (2017)

Hybrid atrial fibrillation ablation in patients with persistent atrial fibrillation or failed catheter ablation
por: Al-Jazairi, M. I. H., et al.
Publicado: (2019)

Long-term outcome of targeted therapy of underlying conditions in patients with early persistent atrial fibrillation and heart failure: data of the RACE 3 trial
por: Nguyen, Bao Oanh, et al.
Publicado: (2021)

Clustering of cardiovascular and renal comorbidities and risk of incident atrial fibrillation in the community-based PREVEND cohort
por: Van Deutekom, C, et al.
Publicado: (2023)

Effects of a simple cardiac rehabilitation program on improvement of self-reported physical activity in atrial fibrillation – Data from the RACE 3 study
por: Nguyen, Bao Oanh, et al.
Publicado: (2020)

Pathophysiological pathways in patients with heart failure and atrial fibrillation( )
por: Santema, Bernadet T, et al.
Publicado: (2021)

Atrial fibrillation and left atrial size and function: a Mendelian randomization study
por: van de Vegte, Yordi J., et al.
Publicado: (2021)

Relation of overweight and symptomatic atrial fibrillation: A case report
por: de Maat, Gijs E., et al.
Publicado: (2015)

Antiarrhythmic drugs in patients with early persistent atrial fibrillation and heart failure: results of the RACE 3 study
por: Al-Jazairi, Meelad I H, et al.
Publicado: (2021)

Effectiveness and safety of dabigatran versus acenocoumarol in ‘real-world’ patients with atrial fibrillation
por: Korenstra, Jennie, et al.
Publicado: (2016)

Identifying patients with atrial fibrillation recurrences after two pulmonary vein isolation procedures
por: Mulder, Bart A, et al.
Publicado: (2021)

Integrated care in patients with atrial fibrillation- a predictive heterogeneous treatment effect analysis of the ALL-IN trial
por: Trinks-Roerdink, Emmy M., et al.
Publicado: (2023)

Young-onset atrial fibrillation: Sex differences in clinical profile, progression rate and cardiovascular outcome()
por: Marcos, Ernaldo G., et al.
Publicado: (2019)

Sex-related differences in risk factors, outcome, and quality of life in patients with permanent atrial fibrillation: results from the RACE II study
por: Kloosterman, Mariëlle, et al.
Publicado: (2019)

Reappraisal of Atrial fibrillation: interaction between hyperCoagulability, Electrical remodelling and Vascular destabilisation in the progression of AF (RACE V) Tissue Bank Project: study design
por: Gilbers, M. D., et al.
Publicado: (2021)

Opportunities and challenges of large-scale screening for atrial fibrillation
por: Zink, Matthias Daniel, et al.
Publicado: (2018)

Considerations for the Assessment of Substrates, Genetics and Risk Factors in Patients with Atrial Fibrillation
por: Linz, Dominik, et al.
Publicado: (2021)

Genetic risk and atrial fibrillation in patients with heart failure
por: Kloosterman, Mariëlle, et al.
Publicado: (2020)

Newly discovered atrial fibrillation: who(se) care(s)?
por: Crijns, Harry J G M, et al.
Publicado: (2020)

Paradigm shifts in pathophysiology and management of atrial fibrillation—a tale of the RACE trials in the Netherlands
por: Crijns, H. J. G. M., et al.
Publicado: (2020)

Atrial fibrillation detected at screening is not a benign condition: outcomes in screen-detected versus clinically detected atrial fibrillation. Results from the Prevention of Renal and Vascular End-stage Disease (PREVEND) study
por: Zwartkruis, Victor W, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l1r2bfjgvbj3mkp8hm94e97iqc